Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

Lori J. Wirth, MD, associate professor of medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the phase 3 LIBRETTO-531 trial (NCT04211337) of selpercatinib (Retevmo) in patients with RET-mutant medullary thyroid cancer. 

The multicenter, randomized, open-label phase 3 trial is currently underway, Wirth says, and it is comparing the use of selpercatinib with physician’s choice of vandetanib (Caprelsa) or cabozantinib (Cabometyx) in those with progressive, advanced disease that is naïve to kinase inhibitors. In the trial, if patients who receive treatment with either vandetanib or cabozantinib experience disease progression, they have the opportunity to crossover to receive selpercatinib, Wirth explains.

The primary end point of LIBRETTO-531 is treatment failure-free survival, With adds. This trial might shed light on how to better sequence gene-specific therapy with a multikinase inhibitor in this patient population, Wirth concludes.